We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo posted Q3 adjusted EPS of $0.80, topping estimates but down 1.2% year over year.
Net sales fell 4.1% to $1.04B, hurt by weak infant formula and oral care performance.
Perrigo cut 2025 sales and EPS guidance and began a strategic review of its infant formula business.
Perrigo (PRGO - Free Report) reported adjusted earnings of 80 cents per share in the third quarter of 2025, beating the Zacks Consensus Estimate of 75 cents. The reported figure fell 1.2% year over year, attributable to lower sales volume in the quarter.
Net sales declined 4.1% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.10 billion. The downside was due to the soft sales performance of its infant formula and oral care businesses, as well as the loss of sales stemming from exited businesses and product lines, partially offset by favorable currency movements.
In the quarter, sales dropped 1.3% year over year on account of exited businesses and product lines, but benefited 1.6% from favorable currency movements. At constant currency (excluding foreign currency translation), sales fell 5.7%. Organic net sales (excluding the effects of acquisitions and divestitures, and the impacts of currency) declined 4.4%.
More on PRGO’s Earnings
Perrigo reports its results under the following segments: Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”).
CSCA: The segment’s net sales in the quarter came in at $646 million, down 3.8% year over year. Though sales grew across the Upper Respiratory, Skin Care and Women’s Health categories, more than offset by lower sales in the Infant Formula and Oral Care businesses. Organic net sales also declined 3.8%. The reported segment sales missed the Zacks Consensus Estimate of $664 million and our model estimate of $676 million.
CSCI: The segment reported net sales of $398 million, down 4.5% from the year-ago period due to the soft sales performances of its Upper Respiratory, VMS (Vitamins, Minerals and Supplements), and Women's Health categories. This decline was partially offset by favorable currency movements in the quarter. At constant-currency rates, sales moved down 8.7% year over year. Organically, sales declined 5.3%. CSCI sales missed the Zacks Consensus Estimate and our model estimate of $432 million and $429 million, respectively.
PRGO’s 2025 Guidance
Perrigo lowered its financial guidance for total sales this year due to infant formula industry dynamics and challenging market consumption trends. As a result, the company expects sales to decline 2.5-3% against the previously issued guidance of growth in sales toward the lower end of 0-3%. This revision was likely the reason for the 12% decline in Perrigo’s stock price during pre-market trading today.
Year to date, shares of Perrigo have lost more than 21% against the industry’s 1% growth.
Image Source: Zacks Investment Research
Perrigo also lowered some of its other 2025 financial targets, including an adjusted EPS of $2.70-$2.80 (previously: $2.90-$3.10) and an adjusted gross margin of 39% (previously: 40%). The company reiterated its guidance for the adjusted operating margin near 15%.
Perrigo to Conduct Strategic Review of Infant Formula Biz
In a separate press release, the company announced it is initiating a strategic review of its infant formula business — a unit expected to generate $360 million in net sales in 2025, yet representing less than 10% of its total annual net sales. This review, which is part of Perrigo’s “Three-S” (Stabilize, Streamline, Strengthen) plan, aims to evaluate a full range of alternatives to maximize shareholder value. The company has not set any specific timeline for completing this process.
EPS estimates for Alkermes’ 2025 have increased from $1.78 to $1.96, while those for 2026 have risen from $1.69 to $1.77 in the past 60 days. ALKS stock has gained 6% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average negative surprise of 4.58%.
In the past 60 days, estimates for CorMedix’s earnings per share (EPS) have increased from $1.24 to $1.85 for 2025. During the same time, EPS estimates for 2026 have increased from $2.09 to $2.49. Year to date, shares of CRMD have rallied 41%.
CorMedix’s earnings beat estimates in the trailing four quarters, the average surprise being 34.85%.
In the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $7.25 to $7.29 for 2025. In the same time, EPS estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 71%.
ANI Pharmaceuticals' earnings beat estimates in the trailing four quarters, the average surprise being 22.66%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut
Key Takeaways
Perrigo (PRGO - Free Report) reported adjusted earnings of 80 cents per share in the third quarter of 2025, beating the Zacks Consensus Estimate of 75 cents. The reported figure fell 1.2% year over year, attributable to lower sales volume in the quarter.
Net sales declined 4.1% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.10 billion. The downside was due to the soft sales performance of its infant formula and oral care businesses, as well as the loss of sales stemming from exited businesses and product lines, partially offset by favorable currency movements.
In the quarter, sales dropped 1.3% year over year on account of exited businesses and product lines, but benefited 1.6% from favorable currency movements. At constant currency (excluding foreign currency translation), sales fell 5.7%. Organic net sales (excluding the effects of acquisitions and divestitures, and the impacts of currency) declined 4.4%.
More on PRGO’s Earnings
Perrigo reports its results under the following segments: Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”).
CSCA: The segment’s net sales in the quarter came in at $646 million, down 3.8% year over year. Though sales grew across the Upper Respiratory, Skin Care and Women’s Health categories, more than offset by lower sales in the Infant Formula and Oral Care businesses. Organic net sales also declined 3.8%. The reported segment sales missed the Zacks Consensus Estimate of $664 million and our model estimate of $676 million.
CSCI: The segment reported net sales of $398 million, down 4.5% from the year-ago period due to the soft sales performances of its Upper Respiratory, VMS (Vitamins, Minerals and Supplements), and Women's Health categories. This decline was partially offset by favorable currency movements in the quarter. At constant-currency rates, sales moved down 8.7% year over year. Organically, sales declined 5.3%. CSCI sales missed the Zacks Consensus Estimate and our model estimate of $432 million and $429 million, respectively.
PRGO’s 2025 Guidance
Perrigo lowered its financial guidance for total sales this year due to infant formula industry dynamics and challenging market consumption trends. As a result, the company expects sales to decline 2.5-3% against the previously issued guidance of growth in sales toward the lower end of 0-3%. This revision was likely the reason for the 12% decline in Perrigo’s stock price during pre-market trading today.
Year to date, shares of Perrigo have lost more than 21% against the industry’s 1% growth.
Image Source: Zacks Investment Research
Perrigo also lowered some of its other 2025 financial targets, including an adjusted EPS of $2.70-$2.80 (previously: $2.90-$3.10) and an adjusted gross margin of 39% (previously: 40%). The company reiterated its guidance for the adjusted operating margin near 15%.
Perrigo to Conduct Strategic Review of Infant Formula Biz
In a separate press release, the company announced it is initiating a strategic review of its infant formula business — a unit expected to generate $360 million in net sales in 2025, yet representing less than 10% of its total annual net sales. This review, which is part of Perrigo’s “Three-S” (Stabilize, Streamline, Strengthen) plan, aims to evaluate a full range of alternatives to maximize shareholder value. The company has not set any specific timeline for completing this process.
PRGO’s Zacks Rank
Perrigo currently has a Zacks Rank #4 (Sell).
Perrigo Company plc Price
Perrigo Company plc price | Perrigo Company plc Quote
Better-Ranked Biotech Stocks to Consider
Some better-ranked stocks from the sector are Alkermes (ALKS - Free Report) , CorMedix (CRMD - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) . ALKS and CRMD sport a Zacks Rank #1 (Strong Buy) at present, and ANIP carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
EPS estimates for Alkermes’ 2025 have increased from $1.78 to $1.96, while those for 2026 have risen from $1.69 to $1.77 in the past 60 days. ALKS stock has gained 6% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average negative surprise of 4.58%.
In the past 60 days, estimates for CorMedix’s earnings per share (EPS) have increased from $1.24 to $1.85 for 2025. During the same time, EPS estimates for 2026 have increased from $2.09 to $2.49. Year to date, shares of CRMD have rallied 41%.
CorMedix’s earnings beat estimates in the trailing four quarters, the average surprise being 34.85%.
In the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $7.25 to $7.29 for 2025. In the same time, EPS estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 71%.
ANI Pharmaceuticals' earnings beat estimates in the trailing four quarters, the average surprise being 22.66%.